We are live on
!
Find out more
SCM
Sarissa Capital Management Portfolio holdings
AUM
$158M
1-Year Est. Return
103.7%
This Fund
S&P 500
This Quarter
Est. Return
+7.28%
1 Year Est. Return
+103.7%
3 Year Est. Return
+58.62%
5 Year Est. Return
+92.85%
10 Year Est. Return
+667.68%
AUM
$1.27B
AUM Growth
+$16.3M
(+1.3%)
Cap. Flow
-$25M
Cap. Flow
% of AUM
-1.96%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
15
New
1
Increased
4
Reduced
1
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AMRN
Amarin Corp
AMRN
|
+$41.8M |
| 2 |
Alkermes
ALKS
|
+$37.9M |
| 3 |
Gilead Sciences
GILD
|
+$19M |
| 4 |
MRSN
Mersana Therapeutics
MRSN
|
+$3.43M |
| 5 |
Innoviva
INVA
|
+$2.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$119M |
| 2 |
BioCryst Pharmaceuticals
BCRX
|
+$5.27M |
| 3 |
SRSAW
Sarissa Capital Acquisition Corp. Warrants
SRSAW
|
+$5M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$177K |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$161K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alkermes
ALKS
$8.22B
| $407M | 31.99% |
13,213,000
+1,343,000
| +11% | +$37.9M |
|
2
Ironwood Pharmaceuticals
IRWD
$696M
| $214M | 16.8% |
16,390,000
| – | – |
|
|
3
Gilead Sciences
GILD
$162B
| $207M | 16.27% |
2,967,300
+269,900
| +10% | +$19M |
|
4
Biogen
BIIB
$30B
| $182M | 14.28% |
643,000
| – | – |
|
|
5
Innoviva
INVA
$1.55B
| $111M | 8.68% |
6,614,000
+200,000
| +3% | +$2.99M |
|
|
6
BioCryst Pharmaceuticals
BCRX
$2.28B
| $56.4M | 4.43% |
3,926,700
-334,300
| -8% | -$5.27M |
|
|
AMRN
7
Amarin Corp
AMRN
$299M
| $43.4M | 3.4% |
+425,000
| New | +$41.8M |
|
|
MRSN
8
DELISTED
Mersana Therapeutics
MRSN
| $40.5M | 3.18% |
171,972
+11,748
| +7% | +$3.43M |
|
9
Vor Biopharma
VOR
$1.15B
| $11.1M | 0.87% |
35,351
| – | – |
|
|
RGLS
10
DELISTED
Regulus Therapeutics
RGLS
| $1.28M | 0.1% |
185,185
| – | – |
|
|
11
Jazz Pharmaceuticals
JAZZ
$15.9B
| – | – |
-1,000
| Closed | -$177K |
|
|
MRTX
12
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-1,000
| Closed | -$161K |
|
|
ICPT
13
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| – | – |
-950
| Closed | -$18K |
|
|
SRSAW
14
DELISTED
Sarissa Capital Acquisition Corp. Warrants
SRSAW
| – | – |
-3,333,333
| Closed | -$5M |
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| – | – |
-650,440
| Closed | -$119M |
|
Similar funds
4A
DAM
PCP
CF
HEM
SF
AC
EP
Sarissa Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Sarissa Capital Management held 15 positions worth $1.27B, up 1.3% from $1.26B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Sarissa Capital Management's Q3 2021 filing shows 1 new, 4 increased, 1 reduced and 5 closed positions. Its largest new stake was Amarin Corp: 425,000 shares worth $43.4M. The largest sale was Alexion Pharmaceuticals, an estimated $119M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.
- Sarissa Capital Management's largest Q3 2021 buy was Amarin Corp: 425,000 shares worth $43.4M.
- Sarissa Capital Management added most to Alkermes in Q3 2021, an estimated $37.9M increase.
- Sarissa Capital Management's biggest Q3 2021 reduction was BioCryst Pharmaceuticals, cutting an estimated $5.27M.
- Sarissa Capital Management fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $119M.
- Sarissa Capital Management's ten largest holdings make up 100% of its $1.27B portfolio in Q3 2021.
- Sarissa Capital Management opened 1 new position and closed 5 in Q3 2021.
- Sarissa Capital Management's portfolio value rose 1.3% quarter-over-quarter to $1.27B.
Based on Sarissa Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.